Uniqure NV
NASDAQ:QURE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Uniqure NV
Common Shares Outstanding
Uniqure NV
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
Common Shares Outstanding
$62.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Pharming Group NV
AEX:PHARM
|
Common Shares Outstanding
$701.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Common Shares Outstanding
€107.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
|
argenx SE
XBRU:ARGX
|
Common Shares Outstanding
$61.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
15%
|
|
|
Merus NV
NASDAQ:MRUS
|
Common Shares Outstanding
$76m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Common Shares Outstanding
$26m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Common Shares Outstanding?
Common Shares Outstanding
62.3m
USD
Based on the financial report for Dec 31, 2025, Uniqure NV's Common Shares Outstanding amounts to 62.3m USD.
What is Uniqure NV's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
10%
Over the last year, the Common Shares Outstanding growth was 27%. The average annual Common Shares Outstanding growth rates for Uniqure NV have been 10% over the past three years , 7% over the past five years , and 10% over the past ten years .
